The UK healthcare industry is excited with talk of Retatrutide, a innovative dual GIP and GLP-1 receptor offering remarkable potential for obesity treatment. Currently, it's not widely to the NHS but is becoming increasingly popular amongst individuals desiring effective fat reduction methods. A number of pharmacies are already providing the option